New Treatment for Alcoholism-Can Shares Buck the Market Downtrend?

New Treatment for Alcoholism-Can Shares Buck the Market Downtrend?

By: Tomas Ronolski - AllPennyStocks.com News

Thursday, May 19, 2022

Alcoholism has devastating affects on those afflicted and their loved ones. This company is working on way to treat this destructive disease.

Biotechnology firm Clearmind Medicine Inc. (CSE: CMND) (OTC Pink: CMNDF) focuses on the discovery and development of novel psychedelic-derived therapeutics. The company’s press release today announced positive safety results of its proprietary molecule, MEAI, to treat alcohol abuse.

Using groups of mice, the company was able to find positive efficacy on reducing consumption of alcohol. FDA trials on humans are expected later this year. No topological effects of MEAI were found in the animals’ organs.

Both Canadian and U.S. shares were delayed at the open. Canadian shares closed Wednesday at $0.37.



Copyright © 2022 AllPennyStocks.com. All rights reserved. Republication or redistribution of AllPennyStocks.com's content is expressly prohibited without the prior written consent of AllPennyStocks.com. AllPennyStocks.com shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Other Penny Stock Movers

Shares of Dual-Listed Miner Up on News of Options on Uranium Properties
Shares Up as Firm Launches First Short Spot Bitcoin ETP in the Nordics
Could This Stock Be The Next Big Mover In The Short-Term Rental Market?
Most Popular
FREE Newsletter


Back to Top